Omeros Drug Test Shows Postoperative Benefits

Seattle-based pharmaceutical company Omeros announced positive results from its final Phase 3 clinical trial of OMS302, a drug added to irrigation solutions after cataract or lens replacement surgery.

Advertisement

 

In November, Omeros announced the results from the clinical trial showed the drug met co-primary efficacy endpoints with better pupil dilation and pain reduction after surgery.

 

More Articles on Ophthalmology:

56 Physician-Owned Hospitals to Know
20 Physicians Scattered Throughout 113th Congress
Ophthalmologist on the Move: Dr. Augustus Stern Joins MD’s Bergman Eye Center

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.